The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective

Batista, Sílvia; Gregório, Ana C.; Otake, Andréia Hanada; Couto, Nuno; Costa-Silva, Bruno

doi:10.1155/2019/6240505

Cited by 13 publications

(7 citation statements)

References 268 publications

(261 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The tumor microenvironment remains to be the main battlefield between the tumor and host immunity, whereas the cross-talk between them seems to be important [ [34] , [35] , [36] , [37] ]. Immune cells infiltrated in tumor microenvironment not only receives the signals from tumor cells but also influence the malignant biological behavior of tumor cells.…”

Section: Resultsmentioning

confidence: 99%

Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments

Wang

Jiang

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments

Wang

Jiang

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

“…By secreting IL11, CAFs support distant metastasis through activating Glycoprotein 130 (GP130)/STAT3 signaling in PDAC cells ( 106 ). Also, increased STAT3 activity in CD11b+myeloid cells, motivates the local invasion of primary tumor cells into the blood or lymphatic vessels to move towards the metastatic sites and create pre-metastatic niche ( 107 ). Studies have shown that exosomes derived from PDAC can induce the formation of pre-metastatic niche in liver.…”

Section: Immune-related Cellular Biology In the Progression Of Pdacmentioning

confidence: 99%

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma

Zhang

Huang

2022

Front. Oncol.

View full text Add to dashboard Cite

Pancreatic cancer has the seventh highest death rate of all cancers. The absence of any serious symptoms, coupled with a lack of early prognostic and diagnostic markers, makes the disease untreatable in most cases. This leads to a delay in diagnosis and the disease progresses so there is no cure. Only about 20% of cases are diagnosed early. Surgical removal is the preferred treatment for cancer, but chemotherapy is standard for advanced cancer, although patients can eventually develop drug resistance and serious side effects. Chemoresistance is multifactorial because of the interaction among pancreatic cancer cells, cancer stem cells, and the tumor microenvironment (TME). Nevertheless, more pancreatic cancer patients will benefit from precision treatment and targeted drugs. This review focuses on the immune-related components of TME and the interactions between tumor cells and TME during the development and progression of pancreatic cancer, including immunosuppression, tumor dormancy and escape. Finally, we discussed a variety of immune components-oriented immunotargeting drugs in TME from a clinical perspective.

show abstract

“…Detailed insight into TME components and their role in de novo resistance to checkpoint blockade in GI cancers has recently been reviewed by Batista et al [19], and broadly outlined in Fig. 1.…”

Section: Pre-requisites For Anti-cancer Immunity and The Immune Landsmentioning

confidence: 99%

Targeting the immune milieu in gastrointestinal cancers

2020

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers are among the most common and lethal solid tumors worldwide. Unlike in malignancies such as lung, renal and skin cancers, the activity of immunotherapeutic agents in GI cancers has, on the whole, been much less remarkable and do not apply to the majority. Furthermore, while incremental progress has been made and approvals for use of immune checkpoint inhibitors (ICIs) in specific subsets of patients with GI cancers are coming through, in a population of ‘all-comers’, it is frequently unclear as to who may benefit most due to the relative lack of reliable predictive biomarkers. For most patients with newly diagnosed advanced or metastatic GI cancer, the mainstay of treatment still involves chemotherapy and/or a targeted agent however, beyond the second-line this paradigm confers minimal patient benefit. Thus, current research efforts are concentrating on broadening the applicability of ICIs in GI cancers by combining them with agents designed to beneficially remodel the tumor microenvironment (TME) for more effective anti-cancer immunity with intention of improving patient outcomes. This review will discuss the currently approved ICIs available for the treatment of GI cancers, the strategies underway focusing on combining ICIs with agents that target the TME and touch on recent progress toward identification of predictors of sensitivity to immune checkpoint blockade in GI cancers.

show abstract

The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective

Cited by 13 publications

References 268 publications

Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments

Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma

Targeting the immune milieu in gastrointestinal cancers

Contact Info

Product

Resources

About